Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is protected by 3 US drug patents filed in 2015 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humalog Kwikpen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(4 months ago) |
Expired
|
| US6551992 | Stable insulin formulations |
Jun, 2018
(6 years ago) |
Expired
|
| US6034054 | Stable insulin formulations |
Jun, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humalog Kwikpen's patents.
Latest Legal Activities on Humalog Kwikpen's Patents
Given below is the list of recent legal activities going on the following patents of Humalog Kwikpen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2019 | US7291132 |
| Post Issue Communication - Certificate of Correction | 09 Sep, 2008 | US7291132 |
| Post Issue Communication - Certificate of Correction | 23 Jun, 2008 | US7291132 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Nov, 2007 | US7291132 |
| Recordation of Patent Grant Mailed Critical | 06 Nov, 2007 | US7291132 |
| Email Notification Critical | 19 Oct, 2007 | US7291132 |
| Issue Notification Mailed Critical | 17 Oct, 2007 | US7291132 |
| Dispatch to FDC | 04 Oct, 2007 | US7291132 |
| Application Is Considered Ready for Issue Critical | 01 Oct, 2007 | US7291132 |
| Issue Fee Payment Received Critical | 28 Sep, 2007 | US7291132 |
US patents provide insights into the exclusivity only within the United States, but Humalog Kwikpen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humalog Kwikpen's family patents as well as insights into ongoing legal events on those patents.
Humalog Kwikpen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Humalog Kwikpen's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 09, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Humalog Kwikpen Generics:
There are no approved generic versions for Humalog Kwikpen as of now.
Alternative Brands for Humalog Kwikpen
Humalog Kwikpen which is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Lispro Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lilly |
| |||||||||
| Salix Pharms |
| |||||||||
| Sanofi Aventis Us |
| |||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Insulin Lispro Recombinant. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Lilly |
|
About Humalog Kwikpen
Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia. Humalog Kwikpen uses Insulin Lispro Recombinant as an active ingredient. Humalog Kwikpen was launched by Eli Lilly And Co in 2015.
Approval Date:
Humalog Kwikpen was approved by FDA for market use on 26 May, 2015.
Active Ingredient:
Humalog Kwikpen uses Insulin Lispro Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Lispro Recombinant ingredient
Treatment:
Humalog Kwikpen is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia.
Dosage:
Humalog Kwikpen is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200 UNITS/ML | SOLUTION | Prescription | SUBCUTANEOUS |
Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humalog Kwikpen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(4 months ago) |
Expired
|
| US5474978 | Insulin analog formulations |
Jun, 2014
(10 years ago) |
Expired
|
| US5514646 | Insulin analogs modified at position 29 of the B chain |
May, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humalog Kwikpen's patents.
Latest Legal Activities on Humalog Kwikpen's Patents
Given below is the list of recent legal activities going on the following patents of Humalog Kwikpen.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2019 | US7291132 |
| Post Issue Communication - Certificate of Correction | 09 Sep, 2008 | US7291132 |
| Post Issue Communication - Certificate of Correction | 23 Jun, 2008 | US7291132 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Nov, 2007 | US7291132 |
| Recordation of Patent Grant Mailed Critical | 06 Nov, 2007 | US7291132 |
| Email Notification Critical | 19 Oct, 2007 | US7291132 |
| Issue Notification Mailed Critical | 17 Oct, 2007 | US7291132 |
| Dispatch to FDC | 04 Oct, 2007 | US7291132 |
| Application Is Considered Ready for Issue Critical | 01 Oct, 2007 | US7291132 |
| Issue Fee Payment Received Critical | 28 Sep, 2007 | US7291132 |
US patents provide insights into the exclusivity only within the United States, but Humalog Kwikpen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humalog Kwikpen's family patents as well as insights into ongoing legal events on those patents.
Humalog Kwikpen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Humalog Kwikpen's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 09, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Humalog Kwikpen Generics:
There are no approved generic versions for Humalog Kwikpen as of now.
Alternative Brands for Humalog Kwikpen
Humalog Kwikpen which is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Lispro Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lilly |
| |||||||||
| Salix Pharms |
| |||||||||
| Sanofi Aventis Us |
| |||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Insulin Lispro Recombinant. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Lilly |
|
About Humalog Kwikpen
Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia. Humalog Kwikpen uses Insulin Lispro Recombinant as an active ingredient. Humalog Kwikpen was launched by Lilly in 2019.
Approval Date:
Humalog Kwikpen was approved by FDA for market use on 15 November, 2019.
Active Ingredient:
Humalog Kwikpen uses Insulin Lispro Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Lispro Recombinant ingredient
Treatment:
Humalog Kwikpen is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia.
Dosage:
Humalog Kwikpen is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100 UNITS/ML | INJECTABLE | Prescription | INJECTION |